Instil Bio Q2 EPS $(2.29) Beats $(2.98) Estimate
Portfolio Pulse from Benzinga Newsdesk
Instil Bio (NASDAQ:TIL) reported a Q2 EPS loss of $(2.29), beating the analyst consensus estimate of $(2.98) by 23.15%. This represents a 4.09% increase in losses compared to the same period last year.
August 13, 2024 | 9:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Instil Bio reported a Q2 EPS loss of $(2.29), which beat the analyst consensus estimate of $(2.98) by 23.15%. Despite this positive surprise, the losses increased by 4.09% compared to the same period last year.
The better-than-expected EPS loss is a positive indicator and may boost investor confidence in the short term. However, the increase in losses compared to last year could temper some of the enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100